Dr. Stéphanie BOUTILLIER is a neurobiologist, graduated with a PhD in neurosciences in 2002 and has several years of experience in various academic laboratories across Europe, working in particular on understanding the mechanisms underlying the Alzheimer’s disease.

In 2008, she completed an innovation management program at the Strasbourg Business School (EMS). She worked as a Project Manager for a start-up in creation, developing biomarkers for AD.

She joined Firalis Group under Amoneta Diagnostics, in 2014, as a Senior Project Manager in neurodegenerative disease diagnostics, where she contributed to the establishment of the company’s clinical study pipeline, including the proof-of-performance biomarker study ADDIA (H2020) in over 13 clinical sites in 5 countries.

In 2021, she coordinated the operational and organizational aspects of projects of the Group, as the Global Project Manager at Firalis.

Since 2023, Dr. Stéphanie BOUTILLIER is the CEO of Amoneta Diagnostics. ​